Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BICYCLE THERAPEUTICS PLC (BCYC)

Bicycle Therapeutics director Charles Swanton resigns from board and committees

Neutral Impact 2 of 5 leadership Written later

Bicycle Therapeutics plc disclosed that Charles Swanton resigned as a Class II director, from all board committees, and from its Clinical Advisory Board, effective immediately, on August 18, 2026. The company said the resignation was for personal reasons and not due to any disagreement over operations, policies or practices, so the change is administrative in nature for shareholders.

Key points

  • Charles Swanton resigned as a Class II director on August 18, 2026, effective immediately
  • He also resigned from the Board's committees and the Company's Clinical Advisory Board
  • The filing states the resignation was for personal reasons, not a disagreement with the Company

The filing

CompanyBICYCLE THERAPEUTICS PLC (BCYC)
Form8-K, current report
Filed with the SECAug 20, 2026, 4:05 PM ET
Accession number0001104659-26-099221

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.